Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, pr... Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. Show more
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu PR Newswire NEWTOWN, Pa., Dec. 23, 2024 Investigational agent in development for treatment or prevention of H5N1...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 10.33 | 213.871635611 | 4.83 | 19.44 | 4.6977 | 17389 | 5.10294239 | CS |
4 | 10.65 | 236.141906874 | 4.51 | 19.44 | 4.06 | 9765 | 4.93306409 | CS |
12 | 9.14 | 151.827242525 | 6.02 | 19.44 | 4.06 | 9971 | 5.05369266 | CS |
26 | 3.3475 | 28.3386243386 | 11.8125 | 19.44 | 4.06 | 57530 | 8.58491245 | CS |
52 | -9.59 | -38.7474747475 | 24.75 | 24.75 | 4.06 | 74311 | 12.54698352 | CS |
156 | -9.59 | -38.7474747475 | 24.75 | 24.75 | 4.06 | 74311 | 12.54698352 | CS |
260 | -9.59 | -38.7474747475 | 24.75 | 24.75 | 4.06 | 74311 | 12.54698352 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.